… This product class encompasses gene therapy medicines, somatic-cell … be raised by health
technology assessment agencies in the future as more and more advanced therapies request …

… programme or approach for cell and gene therapies, or advanced therapy medicinal products
(ATMPs) more generally, although some have supplemental processes for rare disease …

… data that reaches Health Technology Assessment (HTA) and reimbursement stage can
be insufficient for healthcare systems to assess their added therapeutic value with certainty (…

… The puzzling situation of hospital exemption for advanced therapy medicinal products in
Europe and … hospital exemption definition for advanced therapy medicinal products in Europe. …

… Health technology assessment (HTA) can play an important role in supporting new technologies
… Generally, these methods are introduced in mature technologies that have proved their …

… Additionally, we aimed to include medicines ranging in complexity (from advanced therapeutic
medicinal products (ATMPs) … Advanced therapy medicinal products and health technology …

… , several countries have created strategies to manage advanced therapy products.
Methods … Advanced therapy medicinal products are defined as cell, gene, and tissue-engineered …

… On the basis of the life cycle concept of health technologies (see Figure 1), this article will
go through some of these initiatives and define the role that Health Technology Assessment …

… for analysts conducting economic evaluations of advanced therapy medicinal products (ATMPs):
(1) … Health technology assessment (HTA) organizations typically assess value based on …

… that advanced therapy medicinal products (ATMPs) aim at diseases of high unmet medical
… coverage recommendations based on how health technology assessment (HTA) agencies …